Name of the interactor | pVHL AA involved | Missense mutations count N (%) | Frequency of observed missense mutations compared to expected | p-value | Pathway of the interactor |
---|---|---|---|---|---|
CK2 | S33, S38, S43 | 0 (0) | lower | ns | Protein amino acid phosphorylation |
GSK3 | S68 | 1 (1.1) | 1.8X higher | ns | Wnt signaling pathway |
CK1 | S72 | 1 (1.1) | 1.8X higher | ns | Wnt signaling pathway |
NEDD8 | K159 | 1 (1.1) | 1.8X higher | ns | Ubl conjugation pathway |
KIFAP3 | 1–54 | 0 (0) | lower | ns | Microtubule-based movement |
HIF1αN | 1–155 | 68 (77.3) | 1.2X higher | ** | HIF1α pathway |
VDU1/USP33 | 54–83 | 22 (25) | 1.3X higher | ns | Ubl conjugation pathway |
VDU2/USP20 | 54–83 | 22 (25) | 1.3X higher | ns | Ubl conjugation pathway |
RPB7 | 54–113 | 39 (44.3) | 1.2X higher | ns | Regulatory RNA pathways |
VHLAK | 54–213 | 88 (100) | equal | not applicable | Apoptosis |
BCL2L11 | 55–143 | 62 (70.5) | 1.3X higher | ** | Apoptosis |
HIF1α | 67–117 | 45 (51.1) | 1.6X higher | *** | Hif1_tf pathway |
EPAS1 (HIF2α) | 67–117 | 45 (51.1) | 1.6X higher | *** | Vegfr1_2 pathway |
RPB1 | 60–120 | 53 (60.2) | 1.6X higher | *** | Regulatory RNA pathways |
PRKCZ | 87–122 | 30 (34.1) | 1.5X higher | ** | Antiapoptosis, intracellular Signaling |
CARD9 | 92–121 | 22 (25) | 1.3X higher | ns | NFKB and MAPK signalling |
TUBA4A | 95–123 | 20 (22.7) | 1.3X higher | ns | MT stabilization and dynamic cell polarity |
KIF3A | 95–123 | 20 (22.7) | 1.3X higher | ns | Hedgehog_gli pathway |
SP1 | 96–122 | 20 (22.7) | 1.3X higher | ns | TGF-beta signaling pathway |
JADE1 | 96–122 | 20 (22.7) | 1.3X higher | ns | Apoptosis |
PRKCD | 113–122, 130–154 | 26 (29.5) | 1.4X higher | ns | Regulation of receptor activity, senescence |
aPKC-λ/ι | 114–122 | 16 (18.2) | 3.2X higher | *** | Signalling by NGF |
EEF1α1 | 114–138 | 23 (26.1) | 1.7X higher | ** | Protein biosynthesis |
CCT-ζ-2 | 116–119, 148–155 | 13 (14.8) | 2X higher | ** | Chaperone-mediated protein complex assembly |
TBP1 | 136–154 | 7 (8) | 1.5X lower | ns | Signaling by Wnt, DNA Replication, Apoptosis |
p53 | 154–163 | 8 (9.1) | 1.5X higher | ns | Apoptosis |
Nur77 | 155–213 | 20 (22.7) | 1.6X lower | ** | MAPK and NGF signaling pathways |
EloC | 157–171 | 11 (12.5) | 1.3X higher | ns | Ubl conjugation pathway |
HuR (RNA binding protein) | 157–184 | 19 (21.6) | 1.2X higher | ns | mRNA stabilization |
EloB | 170–174 | 1 (1.1) | 2.8X lower | ns | Ubl conjugation pathway |
Cullin2 | 181–184 | 6 (6.8) | 2.7X higher | ** | Ubl conjugation pathway |
VBP1 | 187–213 | 1 (1.1) | 14.9X lower | *** | Morphogenesis |